Glaxo strikes $1.9 billion deal for Sierra Oncology

By Ian Walker

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.

GlaxoSmithKline will pay $55 per share in cash, a 39% premium to its closing price of $39.52 on Tuesday. The deal has the support of Sierra’s board as well as shareholders owning 28% of its stock.

Glaxo reaffirmed its guidance. It expects 2021-2026 sales growth of more than 5% and for 10% adjusted operating profit.

The deal is expected to close in the third quarter of this year.

Write to Ian Walker at

This article was originally published by Read the original article here.

Previous articleMarket Extra: Peak inflation? What’s next for U.S. as markets debate hottest CPI in more than 40 years.
Next articleDow Jones Newswires: Tesco profit jumps as revenue rises faster than forecast


Please enter your comment!
Please enter your name here